Øystein Rekdal
Fortune : 201 262 $ au 31/05/2026
Fortune : 201 262 $ au 31/05/2026
Øystein Rekdal is the founder of Lytix Biopharma AS, serving as Chief Executive Officer & Media Relations Contact since 2019, founded in 2003.
Dr. Rekdal is a Professor at the University of Tromso.
Formerly, Dr. Rekdal worked as Director at Prophylix AS.
Education includes a doctorate from the University of Tromso.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LYTIX BIOPHARMA ASA 0,23 % | 11/12/2025 | 176 179 ( 0,23 % ) | 201 262 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| LYTIX BIOPHARMA ASA | Directeur Général | 11/09/2019 |
University of Tromso
University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Sociétés | Poste | Fin |
|---|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
University of Tromso
University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lytix Biopharma AS
Lytix Biopharma AS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops novel cancer immunotherapies | Health Technology |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national